Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

“SUGARDOWN™ is a first-in-class dietary supplement that offers convenient management of high glycemic index foods. This submission provides Boston Therapeutics with scientific and clinical advantages and mass-market appeal”

"SUGARDOWN™ submission to the FDA for structure and function claims as a dietary supplement complies with United State code 21 CFR 101.93. This establishes the basis for our scientific rationale and the clinical benefits of SUGARDOWN™ such as supporting healthy glycemic index, increased fiber intake, and improved overall digestive health" said Ken Tassey, President, Chief Executive Officer and co-founder of Boston Therapeutics, Inc. www.bostonti.com . "SUGARDOWN™ is a first-in-class dietary supplement that offers convenient management of high glycemic index foods. This submission provides Boston Therapeutics with scientific and clinical advantages and mass-market appeal", added Ken Tassey.

"Collaboration between Boston Therapeutics, Inc. carbohydrate scientists and our experienced business and marketing teams has led to fast track development by a Good Manufacturing Practice (GMP) facility and early marketing of SUGARDOWN™. Under the management of Ken Tassey, and in collaboration with the GMP facility, Boston Therapeutics was able to fulfill an unmet market need. Our Marketing and Information Technology teams have set up state-of-the-art distribution and information centers for customer support", said Dr. David Platt, Chairman and co-founder of Boston Therapeutics Inc.

Ken Tassey is President and Chief Executive Officer of Boston Therapeutics Inc since its inception in June 2009. Mr. Tassey was previously a consultant for various finance and marketing projects with experience in operations, banking, marketing and sales.

Dr. David Platt developed SUGARDOWN™ out of an understanding of the benefits of complex carbohydrates to human health. Dr. Platt co-authored two books about carbohydrate recognition entitled Carbohydrate Drug Design and Galectins.